235 related articles for article (PubMed ID: 32945574)
1. Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
Kusnadi EP; Trigos AS; Cullinane C; Goode DL; Larsson O; Devlin JR; Chan KT; De Souza DP; McConville MJ; McArthur GA; Thomas G; Sanij E; Poortinga G; Hannan RD; Hannan KM; Kang J; Pearson RB
EMBO J; 2020 Nov; 39(21):e105111. PubMed ID: 32945574
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
[TBL] [Abstract][Full Text] [Related]
3. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
4. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.
Woods SJ; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2015 Jul; 1849(7):821-9. PubMed ID: 25464032
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
Bursać S; Prodan Y; Pullen N; Bartek J; Volarević S
Trends Cancer; 2021 Jan; 7(1):57-76. PubMed ID: 32948502
[TBL] [Abstract][Full Text] [Related]
7. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
8. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
Chan JC; Hannan KM; Riddell K; Ng PY; Peck A; Lee RS; Hung S; Astle MV; Bywater M; Wall M; Poortinga G; Jastrzebski K; Sheppard KE; Hemmings BA; Hall MN; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Sci Signal; 2011 Aug; 4(188):ra56. PubMed ID: 21878679
[TBL] [Abstract][Full Text] [Related]
9. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
10. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
11. c-Myc overexpression increases ribosome biogenesis and protein synthesis independent of mTORC1 activation in mouse skeletal muscle.
Mori T; Ato S; Knudsen JR; Henriquez-Olguin C; Li Z; Wakabayashi K; Suginohara T; Higashida K; Tamura Y; Nakazato K; Jensen TE; Ogasawara R
Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E551-E559. PubMed ID: 34423683
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance.
El Hassouni B; Sarkisjan D; Vos JC; Giovannetti E; Peters GJ
Curr Med Chem; 2019; 26(33):6020-6032. PubMed ID: 30501594
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel inhibitors of ribosome biogenesis by innovative high throughput screening strategies.
Scull CE; Zhang Y; Tower N; Rasmussen L; Padmalayam I; Hunter R; Zhai L; Bostwick R; Schneider DA
Biochem J; 2019 Aug; 476(15):2209-2219. PubMed ID: 31341008
[TBL] [Abstract][Full Text] [Related]
14. The pathogenesis of mesothelioma is driven by a dysregulated translatome.
Grosso S; Marini A; Gyuraszova K; Voorde JV; Sfakianos A; Garland GD; Tenor AR; Mordue R; Chernova T; Morone N; Sereno M; Smith CP; Officer L; Farahmand P; Rooney C; Sumpton D; Das M; Teodósio A; Ficken C; Martin MG; Spriggs RV; Sun XM; Bushell M; Sansom OJ; Murphy D; MacFarlane M; Le Quesne JPC; Willis AE
Nat Commun; 2021 Aug; 12(1):4920. PubMed ID: 34389715
[TBL] [Abstract][Full Text] [Related]
15. c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.
Musso L; Mazzini S; Rossini A; Castagnoli L; Scaglioni L; Artali R; Di Nicola M; Zunino F; Dallavalle S
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):615-629. PubMed ID: 29229300
[TBL] [Abstract][Full Text] [Related]
16. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate.
Scala F; Brighenti E; Govoni M; Imbrogno E; Fornari F; Treré D; Montanaro L; Derenzini M
Oncogene; 2016 Feb; 35(8):977-89. PubMed ID: 25961931
[TBL] [Abstract][Full Text] [Related]
17. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
Hein N; Cameron DP; Hannan KM; Nguyen NN; Fong CY; Sornkom J; Wall M; Pavy M; Cullinane C; Diesch J; Devlin JR; George AJ; Sanij E; Quin J; Poortinga G; Verbrugge I; Baker A; Drygin D; Harrison SJ; Rozario JD; Powell JA; Pitson SM; Zuber J; Johnstone RW; Dawson MA; Guthridge MA; Wei A; McArthur GA; Pearson RB; Hannan RD
Blood; 2017 May; 129(21):2882-2895. PubMed ID: 28283481
[TBL] [Abstract][Full Text] [Related]
19. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
20. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
